Adagrasib Boosts PFS, Responses vs Docetaxel in KRAS G12C+ NSCLC
Findings from the KRYSTAL-12 trial support adagrasib as a treatment option for those with disease progression on prior chemotherapy and immunotherapy.
Previous Post
U.S. Foreign Aid Freeze & Dissolution of USAID: Timeline of Events
Next Post
STAT+: Novo Nordisk’s obesity drug Wegovy cleared to treat MASH
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago